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Abstract
Cancer immunotherapy is based on the idea of overcoming the main problems 
in the traditional cancer treatments and enhancing the patient’s long-term survival 
and quality of life. Immunotherapy methods aimed to influence the immune 
system, to detect and eradicate the tumors site and predict the potential results. 
Nowadays, nanomaterials-based immunotherapy approaches are gaining interest 
due to numerous advantages like their ability to target cells and tissues directly and 
reduce the off-target toxicity. Therefore, topics about immune system components, 
nanomaterials, their usage in immunotherapy and the benefits they provide will 
be discussed in this presented book chapter. Immunotherapy can be divided into 
two groups mainly; active and passive immunotherapy including their subtitles 
such as immune checkpoint inhibitors, adoptive immunotherapy, CAR-T therapies, 
vaccines, and monoclonal antibodies. Main classification and the methods will be 
evaluated. Furthermore, state-of-art nanocarriers based immunotherapy methods 
will be mentioned in detail. The terms of size, charge, material type and surface 
modifications of the nanoparticles will be reviewed to understand the interfer-
ence of immune system and nanoparticles and their advantages/disadvantages in 
immunotherapy systems.
Keywords: tumor, cancer immunotherapy, vaccination, immunomodulation,  
antigen receptors, nanoparticles, bottom-up method, top-down method
1. Introduction
Understanding the immune system and its components may enlighten future 
potential treatments to generate disease progression such as cancer. For almost 
30 years, by targeting the immune system by therapeutics brought a totally new 
point of view in the field of cancer treatment. Accordingly, besides the commonly 
preferred cancer treatments, the treatments developed specifically for the patient 
and the diseases come to the forefront. To date, immunotherapy is a method devel-
oped as an alternative to conventional cancer treatments [1, 2]. The immune system 
which is an awareness system based on distinguishing between “self” and “non-
self” works in harmony with cells, related tissues, and organs respectively to protect 
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the organisms. The main goal of the immune system is to defense to battle against 
“enemies”. There are two types of immune responses; humoral and cellular immu-
nity. Humoral immunity is primarily mediated by B and T lymphocytes and their 
products. It is also characterized by a weak response and a strong immunological 
memory. Cellular immunity components are natural killer (NK) cells, eosinophils, 
macrophages, and lymphocytes (B and T cells). Cellular immunity works faster 
than humoral immunity via activation and proliferation of B cells and activation of 
antigen-presenting cells (APCs). Cellular immunity can recognize tumors immedi-
ately, but it does not provide long-term immunity. Specifically, B and T cells primar-
ily mediate the antitumor response. The CD4+ T cells pretend as “helper cells” and 
excrete cytokines relying on their profile either Th1 or Th2. Humoral and cellular 
immunity plays a crucial role in antitumor response [3, 4].
2. Cancer
Today, non-communicable diseases are held accountable as the leading cause 
of death worldwide. Among these diseases, cancer is predicted as one of the most 
important disease in the world that causes deaths and reduces the life quality [5]. 
Soon, it is thought that the number of cancer patients and cancer-related deaths 
will increase [6]. The definition of cancer for the first time in 3000 BC was used 
in inscriptions called the Edwin Smith Papyrus, the part of an ancient Egyptian 
textbook on trauma surgery. Cancer is generally characterized by the growth of 
abnormal cells beyond their normal limits. Cancer disease can affect almost any 
part of the body and has many anatomical and molecular subtypes, each of which 
requires specific treatment strategies. The main factors causing cancer are as fol-
lows; ionizing radiation, ultraviolet rays, age, inadequate physical activity, smoking 
and alcohol consumption, nutrition and diet, chemicals, microorganisms, and 
genetic factors. It is known that environmental factors are much more effective in 
the formation of the disease than hereditary factors. The most important reason 
is stated as mutations that occur in genes. Most cancers are caused by a series of 
mutations that allow cells to divide faster, escape internal and external controls, and 
prevent programmed cell death. As the cells continue to divide under the influence 
of mutations in solid tissue such as organ, bone or muscle the resulting mass is 
called tumor. Solid tumors are classified as; benign (noncancerous) and malignant 
(cancerous). Benign tumors do not have the ability to metastasize; they can only 
grow where they are located. On the other hand, malignant tumors have the ability 
to spread to neighboring tissues and organs from where they are formed. Many 
types of cancer initially show no symptoms. The main symptoms observed can be 
given as; unexplained, and rapid weight loss, fever, malaise, pain, swelling and 
bleeding. However, each type of cancer has its own specific symptoms, so the treat-
ment method of each cancer type differs. Figure 1 shows a schematic representation 
of tumor cells progression.
2.1 Cancer treatment methods
Cancer is an individual disease; hence treatment methods vary from patient to 
patient. The method of treatment should be chosen by considering the degree and 
course of the disease, age and health situation of the patient. Generally, most of the 
patients have the combination of treatment methods. Surgical intervention, radia-
tion therapy, chemotherapy, and hormone therapy are defined as traditional cancer 
treatments in the literature [2]. In recent years, immunotherapy has also been the 
increasingly used method in cancer treatment.
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2.1.1 Surgical intervention
Surgical intervention, a local treatment method, can also be used in the combi-
nation of other treatment methods. It is applied in tumors without metastasis that 
only exist in one area such as solid tumors; but not effective in leukemia and cancer 
types that spread. Also, surgical intervention is preferred when the tumor is in an 
untreatable part of the body by other treatment methods such as radiation therapy or 
chemotherapy (cannot reach the brain). In order to remove the tumor without dam-
aging the neighboring healthy cells, the size of the tumor can be reduced by other 
methods. The surgical intervention method works against cancer in three ways; 
eradicating the entire tumor, debulking a tumor, and palliate the disease symptoms. 
Only eradicating the entire tumor may cure the patients if the cancer cells are located 
in small area at one place. Debulking a tumor is used to reduce the tumors size while 
surgery is combined with other treatment methods. Palliate the symptoms, the last 
way in surgical intervention, is to remove the tumor to reduce the pain or pressure 
caused by the tumor. There are some disadvantages of surgical intervention such as 
the possibility of leaving microscopic residues around the tumor after surgery, the 
health status of the patients, and the success of the surgery [7, 8].
2.1.2 Radiation therapy
Radiation therapy or radiotherapy (RT) is based on the principle of using a 
fairly high dose of radiation to shrink the tumor by killing the cancer cells. There 
Figure 1. 
Schematic representation of tumor cells progression (created with BioRender.com).
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are various types of radiotherapy depends on the general state of the patient and 
disease. The principle of radiation therapy is to destroy cancer cells as possible 
without damaging healthy cells. Because, in the late 20th century, scientist discov-
ered that radiation therapy not only cures cancer cells but also may be the cause of 
cancer itself. The notable side effect, it can kill and harm healthy cells significantly. 
Thereby it has side effects such as hair loss, vomiting, and loss of appetite that 
will affect your daily life. The choice of the exact type of radiation therapy relies 
on several circumstances such as the type, stage, size and location of cancer, and 
medical history of the patients. Reducing the tumor mass by radiation therapy is 
helpful to decrease the pressure of tumor on the nearest healthy cells. Additionally, 
it is used before surgical intervention to shrink tumor mass to make it suitable for 
surgery and after surgery; the microscopic residues on the edge of the tumor can be 
removed much more easily. Also, this method of therapy is very suitable for making 
systemic therapy [9, 10].
2.1.3 Chemotherapy
Chemotherapy (CT), also as chemo, is the most commonly used method in 
cancer treatment. The aim is to kill cancer cells using chemotherapeutic agents. 
This method is developed in the late 20th century and combined with surgery and/
or radiation therapy. Over the years, many chemotherapeutic drugs showed great 
impact and gained success for the treatment of many types of cancer. The aim of 
the treatment can be stated as reducing the size of the tumor, reducing the effects 
of the symptoms seen in the patient, preventing metastasis, and reducing the 
total number of tumor cells in the body. The drugs used in chemotherapy direct 
the cell to death by stopping or decelerating the cancer cell proliferation. Some of 
these drugs are natural and some of them are synthetic. Hair loss, vomiting, loss of 
appetite, fever, diarrhea and fatigue are temporary side effects of the drugs that end 
after the treatment [11, 12].
2.1.4 Hormone therapy
Hormones, in the classical sense, are organic compounds that are synthesized in 
ductless glands such as the pituitary gland, adrenal gland, thyroid gland, and para-
thyroid gland, which are known as endocrine organs, and act on certain target tissue 
that is carried by the blood. All cells communicate with each other via hormones. In 
the human body, hormones either can be small proteins (insulin, etc.) or stimulator 
for a cell to generate new proteins or cease making products. One possible featured 
outcome is cell growth and proliferation. Even though cancer cells are abnormal, they 
still keep the ability to react to signals of hormones. The main idea of hormone-based 
treatments is to deprive cancer cells of hormone signals. Otherwise, they would be 
stimulating to continue dividing. The main theme of the drugs that are used in this 
method relies on preventing the activity of hormone within the target cell or block-
ing the production of the related hormone. Hormone therapy is often preferred for 
the treatment of prostate and breast cancer. Generally, hormone therapy is combined 
with other treatment methods depending on the cancer type. Hormone therapy is 
very suitable for adjuvant and neoadjuvant therapy to reduce tumor mass. The term 
adjuvant therapy is about reducing the risk of cancer recurrence after major cancer 
treatment. Hormone therapy is also appropriate for the removal of cancer cells that 
spread to different parts of the body. Like all other methods, hormone therapy has 
common side effects. But these effects depend on the body’s response to the therapy 
and the type of hormone therapy. Side effects are influenced by different terms such 
as patients’ sex and type of hormone that is used. Hot flashes, weakened bones, 
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nausea, and fatigue are common side effects for men. Menstrual irregularities for 
women who are not menopausal and vaginal dryness are seen in addition to the 
common side effects. To date, there are several hormone based drugs based on the 
hormonal signals, but their principles are diverse from each other. They all attack 
different parts of the pathways to decelerate to the growth of cancer [13].
2.1.5 Immunotherapy
Nowadays, cancer treatment is moving from non-specific methods to specific 
methods. Although success is achieved in the destruction of tumors with surgery 
and radiotherapy, cancer may recur due to cancerous cell debris in the damaged area. 
Cancer immunotherapy, an individualized method, is referred to as the “fifth step” of 
the treatment following the traditional methods mentioned above [14]. The immuno-
therapy method; boost the immune system to fight against cancer, train the immune 
system component’s to memory, attack the cancer cells, and heighten the immune 
response via biological substances. For the last decades, immunotherapy becomes 
a promising method to fight against cancer. Immunotherapy can be applied using 
either external substances or their body cells [4].
3. Historical background of cancer immunotherapy
It is common knowledge that many cases of regression of tumor growth after 
high fever attacks or infectious diseases have been reported throughout history 
from Ancient Egypt to the 18th century. However, the relationship between the 
immune system and cancer was noticed in the middle of the 18th century with 
the developing technology. In the mid-18th century, two German doctors, Busch 
and Fehleisen, independently reported cases of tumor regressions of patients 
after erysipelas infection (Streptococcus pyogenes infection). In the literature, the 
first systematic immunotherapy study for the treatment of malignant tumors 
was conducted in 1891 by William B. Coley, a surgical oncologist. Coley injected 
the heat-inactivated Streptococcus pyogenes and Serratia marcescens organisms into 
the patient to stimulate the patient’s immune system. After the project that he 
initiated, Coley has seen a regression in the tumor in more than 1000 sarcoma 
patients who cannot undergo surgical intervention. In a very short time, humanity 
evaluated this mixture as a great invention, “Coley Toxins”. However, the word 
“toxin” was an unfortunate choice; the more acceptable name for the treatment 
was “mixed bacteria vaccine”. Although the bacteria had some side effects such as 
fever and malaise, it is not as toxic as chemotherapy or radiotherapy and does not 
destroy the immune system [15, 16]. Coley’s life-long cancer immunotherapy stud-
ies that will spearhead for many scientists have started after this project. In 1900, 
Paul Ehrlich stated that the first findings of the treatment, which would later be 
called antibody-mediated passive immunotherapy, had an important place in the 
treatment of tumors. In 1975, George Köhler and Cesar Milstein developed hybrid-
oma technology for monoclonal antibody production. This was followed by the 
first successful use of monoclonal adults in human neoplasia in 1982 and the FDA 
(US Food and Drug Administration) approval of muromonab-CD3 (Orthoclone 
OKT3) in 1986. In 1997, both the first humanized monoclonal antibody, dacli-
zumab (Zenapax), and the first monoclonal antibody for malignancy, rituximab 
(Rituxan), were approved by the FDA. This was followed by the FDA approval of 
gemtuzumab ozogamicin (Mylotarg) in 2000, the first toxin-bound monoclonal 
antibody, and ibritumomab tiuxetan (Zevalin) in 2002, the first radionuclide-
bound monoclonal antibody [17].
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Another area that cancer immunotherapy has advanced was using the 
patient’s body cells. In the 1960s, the tumor immune surveillance hypothesis 
was put forward by Burnet. Since 1995, persuasive studies on effective tumor-
specific immunity have attracted great interest. In particular, many studies show 
the ability of dendritic cells to elicit tumor-specific T cell immunity has led to 
this situation. Following preclinical researches, many studies involving various 
types of cancer have been conducted in patients. Recent studies have also made 
the immunosurveillance hypothesis quite popular [18, 19]. Immunotherapy 
studies have increased their importance in the 21st century with the licensing 
of clinical studies carried out with developing technology and methods [20]. 
Immunotherapy was declared as “breakthrough of the year” by Science magazine 
in 2013 after the clinical success achieved and has become even more promi-
nent. Also, in 2018 James Allison and Tasuku Honjo received the Nobel Prize in 
Physiology and Medicine for their work based on the use of the immune system 
to destroy cancer cells. In the past two decades, great strides have been made in 
cancer immunotherapy. With all these spectacular developments, the number 
of cancer immunotherapy studies is increasing day by day [21, 22]. There are 
certain categories in cancer immunotherapy applications. These are the mecha-
nism of innate and acquired immune resistance, internal and external resistance 
to immunotherapy, self-neutralization of tumor cells and antigen- presenting 
cells, inhibition of immunity by exosome release mechanisms, the response of 
tumor cells to therapy. Like all other methods, cancer immunotherapy has several 
advantages and disadvantages. Higher precision and specificity, long-term 
survival rate, fewer side effects than traditional treatment methods, removing 
residual tumor cells and microscopic lesions that remain in the body after treat-
ment and improving the body’s immune function are the advantages of immu-
notherapy. Also, it can control and kill more than one tumor type and it uses the 
body’s immune system to increase immune response. Higher treatment costs, 
various non-specific toxic side effects after treatment are the disadvantages of 
immunotherapy. There is a high selectivity for patients in treatment. When the 
tumor type is “immunosuppressant type” or “immune exclusion type”, the effect 
of immunotherapy treatment is considerably weak. Additionally, in particular, 
the use of immune checkpoint inhibitors can have adverse consequences leading 
to autoimmune diseases and even death [23].
4. Classification of immunotherapy
Cancer immunotherapy is generally classified in three ways; passive, active and 
combination immunotherapy depending on the mechanism of the therapeutic 
agent and the state of the patient’s immune system. Classification of passive and 
active cancer immunotherapy studies is shown in Table 1.
4.1 Passive immunotherapy
The main purpose of passive immunotherapy is to increase the current anti-
tumor response by using therapeutics that can be produced under laboratory 
conditions. It is preferred to use the treatment in patients with weak or dysfunc-
tional immune systems. It is designed to attack tumor cells independently by 
modifying the components of the immune system in the laboratory. Monoclonal 
antibodies and adoptive cell therapy are frequently used passive immunotherapy 
methods [4, 20, 24].
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4.1.1 Monoclonal antibodies
For the past 20 years, monoclonal antibodies are the most commonly used FDA 
approved treatment in clinical immunotherapy studies. They are large artificial 
proteins with high antigen specificity produced by particular B cells. Due to their 
antigen specificity, their capacity to bind to epitopes on the surface of the tumor cell 
is high [25]. So, antibodies specific to antigens of cancer cells are produced in ex vivo 
conditions and transferred to the patient to increase the immune response. Antibodies 
in these targeted therapies are guided directly to the antigen on the surface of cancer 
cells. Different signaling functions can be created by the interaction of monoclonal 
antibodies and receptors on the surface of malignant tumors. Antibodies are used in 
treatment can be classified as naked, conjugated, radiolabeled, chemically labeled, 
and bispecific monoclonal antibodies. Naked monoclonal antibodies are most com-
monly used in cancer immunotherapy and bind directly to the antigen without any 
radioactive markers or drugs. Conjugated monoclonal antibodies are used to transfer 
chemotherapeutic drugs or radiolabeled particles to cancer cells. Radiolabeled mono-
clonal antibodies are created by adding radioactive particles to naked antibodies. 
Chemically labeled antibodies are monoclonal antibodies with a high chemotherapeu-
tic effect. Radioactive or chemically labeled monoclonal antibodies aim to destroy the 
target cell with the toxins they contain or the radiation they emit. Bispecific antibod-
ies carry two types of antibodies in their structure and can bind to two different anti-
gens that are receptors for these two antibodies at the same time [18, 26, 27]. The first 
drug including monoclonal antibodies approved by the FDA was rituximab (Rituxan, 
Genentech) was used in the clinic at 1997. Today, with developing technology, many 
new drugs have emerged for the treatment of different types of cancer [25].
4.1.2 Adoptive cell therapy
It gathered speed with the studies carried out in the 20th century about the dis-
covery of tumor-specific antigens located not on healthy cells but just on the tumor 
cells. Thus the importance of adoptive T cell transfer has been understood. Adoptive 
cell therapy is the transfer of natural or genetically modified T cells to patients in 
ex vivo conditions instead of stimulating the immune system. The transferred cells 
can be autologous or allogeneic targeted to a particular antigen in the host cell. It 
was pointed out that the stage of an immune response in the host is skipped directly 
by this step. To create a targeted immune response, autologous cells can recognize 
tumor antigens, move towards the tumor and exit the circulation. The transfer of T 
cells to destroy tumor cells is carried out in two ways; the infiltrating (TIL) of tumor 
specific T cells from existing tumor cells and the use of genetically modified T cells 
to specifically identify tumor cells. In both methods, the T cell is processed ex vivo 
and then transferred back to the patient [28]. The first successful cellular therapy in 
history was performed on an advanced melanoma patient with autologous TIL. The 
specific T cell receptor (TCR) is obtained by genetically modifying T cells. T cells 
Passive immunotherapy Active immunotherapy
NON-SPECIFIC Adoptive Cell Therapy Cytokines
Immune Checkpoint Inhibitors
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and tumor-specific antigens are matched with HLA recognition by TCR technol-
ogy. A minimal cytotoxic effect occurs by this natural pairing. TCRs also have 
disadvantages such as the low expression on the surface and short lifespan of T cells 
in vivo. Although the first studies ended up with disappointment, today, the other 
genetically modified T cell is chimeric antigen receptors, CAR. Many studies are 
conducted around the world on CAR-T technology and it is believed that positive 
results will be achieved in the near future [29, 30].
4.2 Active immunotherapy
Active immunotherapy aims to destroy cancer cells by stimulating the immune 
system by vaccination, immunomodulation, or targeting specific antigen receptors. 
The method is carried out employing cancer vaccines, oncolytic viruses, immune 
checkpoint inhibitors, and cytokines [20].
4.2.1 Cancer vaccines
The purpose of vaccination is to create an immune response to detect and 
destroy cancer cells. Cancer vaccines, containing whole, part, or purified antigens 
of tumor cells, can be peptide-based, immune cell or dendritic cell-based, or tumor 
cell-based. After the tumor cells are removed from the body, the patient is vac-
cinated and an immune response is created against the tumor cells that may remain 
in the body. Variable antigen expression, low immune response, diminishing the 
immune response in the tumor microenvironment and a decrease in activity over 
time are the restrictions of the cancer vaccine applications [4, 25].
• Peptide-based vaccines are designed to create an immune response against tumor 
antigens that interact with HLA molecules on the surface of tumor cells. Their 
toxic effects on healthy cells are low due to their antigen-specific design, but tumor 
antigen peptides and the patient’s HLA type should be well characterized [31].
• Immune or dendritic cell-based vaccines consist of the use of tumor-asso-
ciated antigens or autologous tumor cells and dendritic cells (DC) obtained 
from monocyte cells in early-stage cancer vaccines. In 2010, the drug called 
Sipuleucel-T (Provenge, Dendreon Corp.) is the first DC-based cancer vac-
cine was approved by the FDA for the treatment of prostate cancer. DC-based 
vaccines today use innovative in vitro culturing techniques enriched with 
cytokines, enhancing immunogenicity and improving DC function. DC-based 
cancer vaccines can be designed differently for both ex vivo and in vivo applica-
tions for various cancer types [4].
• Tumor cell-based cancer vaccines use the entire tumor cell to create an 
immune response. Unlike peptide-based vaccines, tumor cells are not specific 
to antigens on their surface, but the range of epitopes to which they can bind 
is wider. These vaccines can be prepared using the patient’s cells (autologous) 
or using another patient’s tumor cells (allogeneic). Tumor cell-based vaccines 
such as M-Vax (AVAX Technologies) can be used in the treatment of many 
different types of cancer in clinical studies [25].
4.2.2 Oncolytic viruses
These are called genetically altered viruses that can naturally penetrate only 
cancer cells and kill them. Talimogene laherparepvec (T-Vec) is the first oncolytic 
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virus-based drug, approved by the FDA, that the protection mechanisms developed 
against viral infections are impaired in most cancer cells. By taking advantage of this 
degradation, viruses can reproduce more intensely in cancer cells than healthy cells. 
Recently, replication specific to cancer cells was obtained and a reovirus variant called 
Reolysin (exhibiting oncolytic behavior in cells with activated Ras signaling pathway) 
has been developed. In 1991, positive results were gained in the treatment of brain 
cancer with a mutation in a genetically modified type 1 herpes simplex virus [32].
4.2.3 Immune checkpoint inhibitors
Several inhibitory receptors and ligands expressed on T cells, antigen-presenting 
cells, and tumor cells have recently been important elements of immunosuppres-
sion in the tumor microenvironment. Because of their biological role as regulators 
of T cell activation, these receptor/ligand pairs have been termed “immune check-
points”. Immune checkpoints are cell membrane proteins involved in the regulation 
of the immune response. Multiple controls or “checkpoints” are present or activated 
to ensure that the immune-inflammatory response is not continuously activated 
after tumor antigens have generated a response. Immune checkpoints are signals 
that can halt an existing immune response. The over -expression of these signals by 
tumor cells affects tumor cell-specific T-cell immunity in the cancer microenviron-
ment. The aim of treatments involving inhibition of the immune checkpoint is to 
use and strengthen the immune system by disrupting the negative immune system. 
In 2011, the drug called Ipilimumab was used in clinical use for melanoma patients 
by using immune control point drugs. As of March 2019, 7 immunotherapy drugs 
based on checkpoints are used in clinical practice. Monoclonal antibodies that bind 
to immune checkpoints bind with cytotoxic T lymphocyte-associated molecule-4 
(CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death 
ligand (PDL-1) [33].
• PD-1/PDL-1, under normal circumstances, PD-1 has two ligands; PD-L1 and 
PD-L2. Blocking the interaction between PD-1 and PDL-1 with antibodies 
enhances the immune response against cancer cells, “releases the brakes” in the 
immune system and allows for the attack of tumor cells that express PDL-1. 
Nivolumab and Pembrolizumab are the first two drugs approved by the FDA in 
2014 [34].
• CTLA-4 inhibition increases the activation of cytotoxic T cells. Thus, immune 
blockade due to Treg cells is inhibited and antitumor activation is observed. 
Ipilimumab is the first drug approved by the FDA for CTLA-4 treatment in 
2011 [35].
4.2.4 Cytokines
They are the main regulators of innate and adaptive immune systems that allow 
cells of the immune system to communicate in paracrine and autocrine systems over 
short distances. Unlike other therapeutic agents, these molecules directly stimu-
late immune cells, for example Interleukin-21 (IL-21) can act as agents involved 
in active immunotherapy [36]. The use of cytokines in cancer immunotherapy 
showed tumor regression, prevention of metastasis formation, improvement of 
immunological memory and decrease in risk of disease recurrence with increased 
survival. The use of cytokine (IL-2, GM-CSF, IFN-α) -based biological therapy in 
combination with conventional therapies is under clinical development [37]. In 
1986, IFN-α became the first FDA approved cytokine for the treatment of leukemia. 
Cell Interaction - Molecular and Immunological Basis for Disease Management
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Subsequently, IL-2 was approved by the FDA in 1992 for metastatic kidney cancer 
and 1998 for advanced melanoma treatment [36].
4.3 Combinational immunotherapy
Combinational immunotherapy refers the use of a different anticancer agent for 
treatments of cancer. Conjugation of IL-2 and HER-2 monoclonal antibody proved 
to be a very forceful combination in immunotherapy. Lately, PD-1 and CTLA-4 
conjugation has been examined. The results revealed that the combined system was 
safe and had no significant toxic effect [38].
5. Nanoparticles in cancer immunotherapy
Nanoparticle-based biomaterials have a critical role in cancer immunotherapy 
compared with conventional drugs [39]. Immunotherapy often targets tumor cells, 
immune and stromal cells in the tumor microenvironment [40]. Additionally, side 
reactions occurring due to the interactions between nanoparticles (NPs) and cells 
can be adjusted by modifications of nanoparticles [41]. Nanoparticle-based drug 
delivery systems can improve the solubility, in vivo stability, and pharmacokinetic 
profile. Also, they protect drugs from premature release and degradation in the 
living system. These systems can be designed according to the microenvironment 
of the target such as pH, redox potential or enzymes, and external dynamics such 
as light, electrical and magnetic fields. Targeted delivery with NPs can also reduce 
toxicity and immune-related side effects [2]. The size and the shape of the NP are 
very effective in therapeutic efficacy by changing its pharmacokinetics, transporta-
tion, and cellular uptake [42]. Recent advances in nanoparticle formulations have 
generated a wide range of other shapes like rods, prisms, cubes, stars, and discs out 
of spherical. It is considered as non-spherical particles have higher blood circulation 
periods, prolonged margination effects, and higher penetration capacities within 
solid tissues and tumors [43]. The charge of NP has great priority in the transition of 
it into cells. Besides, NP-ligand coupling conditions and the elasticity of NP upgrade 
transportation and accumulation of NP in the living system [44, 45]. Generally, 
it is well known that cationic NPs create a higher immune response than neutral 
or anionic NPs [43]. The size, shape, elasticity, optical, magnetic, and electrical 
properties of nanoparticles can be modified to increase the usage of NPs in cancer 
therapy as a carrier [2, 41, 46]. High specificity, efficacy, diagnosing, imaging, and 
therapeutic properties make NPs candidates in immunotherapy for effective cancer 
treatment. Liposomes, micelles, polymeric, metallic, and inorganic NPs have a wide 
range of usage in cancer immunotherapy [44].
5.1 Classification of nanoparticles
The nanoparticles are generally categorized into tree class as organic, inorganic, 
and carbon-based. Dendrimers, micelles, and liposomes are the most widely 
known organic nanoparticles. These biodegradable, non-toxic, and capsule-shaped 
nanoparticles appear to be an ideal choice for drug delivery due to their sensitivity 
to thermal and electromagnetic radiation. Inorganic nanoparticles, metal, and metal 
oxide-based NPs do not contain carbon in their structure. Aluminum, cadmium, 
cobalt, copper, gold, iron, lead, silver, and zinc can be used to fabricate metallic NPs 
in 10 to 100 nm size range. Carbon-based nanoparticles, fullerenes, graphene, carbon 
nanotubes (CNT), and carbon nanofibers, are build up from carbon in nanosize [47].
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5.2 Preparation methods of nanoparticles
It can be viewed two different ways to synthesize nanoparticles; bottom-up and 
top-down methods (Table 2). These techniques also can be divided as chemical and 
physical methods. Although both methods have positive and negative features, the 
chemical one has more disadvantages due to the wet reaction steps it has [48].
5.2.1 Bottom-up method
It is also known as a constructive method like building-up of material from an 
atom. Sol–gel, spinning, chemical vapor deposition (CVD), pyrolysis, and bio-
synthesis are the foremost methods in this technique. Nanoparticles, nanoshells, 
and nanotubes with narrow size distribution can be synthesized by this approach. 
Besides, in this method deposition parameters can be controlled. However large 
scale production is difficult and chemical purification is needed.
• Sol–gel method: It is a simple, wet chemical process based on hydrolysis and 
polycondensation reactions [49]. This process indicates the chemical transfor-
mation of a system from a “sol” phase, a colloidal solution of solids suspended 
in a liquid phase, into a “gel” phase, a solid macromolecule submerged in a sol-
vent [50]. The chemical and physical properties of the materials as high surface 
area and the stability can be obtained by the method via modifying experimen-
tal conditions. Metal oxide and chloride precursors are used in sol–gel process, 
and then a liquid and a solid phase separation occur after removing precursors 
either by shaking, stirring, or sonication. Nanoparticles are acquired in this 
phase separation by sedimentation, filtration, or centrifugation [47].
• Spinning disc processing (SDP): The method consists of a rotating disc inside 
a reactor generally filled with nitrogen or other inert gases to remove oxygen 
inside and avoid chemical reactions. The purpose of spinning is to merge atoms 
or molecules. The parameters of this process such as the liquid flow rate, disc 
rotation speed, liquid/precursor ratio, location of feed, and disc surface may 
vary for different systems and determine the characteristics of NPs [51].
Top-down approach Bottom-up approach





















Self Assembling Electronic deposition, sol-gel 
method, emulsion, pyrolysis
Table 2. 
Techniques in Top-Down and Bottom-Up approaches.
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• Chemical vapor deposition (CVD): It is the deposition technique of thin films 
of gaseous reactants onto a substrate. Gaseous reactants can be elemental and 
compound semiconductors, metal alloys, and amorphous or crystalline com-
pounds. In the CVD process, a volatile material (chemically reactive) is coming 
together with other gases to produce a nonvolatile solid material that deposit 
at the atomic level on a suitable substrate. This is a well-organized process that 
some kind of reactors should be used depending on the type of precursors, 
deposition conditions, and the forms of the energy introduced to the system 
to stimulate the planned chemical reaction. Metal–organic, plasma-enhanced, 
low-pressure, laser-assisted, and aerosol-assisted CVDs are the most accepted 
methods [52]. The deposition is carried out in a reaction chamber at the 
temperature suitable for the reaction, the substrate is heated and the chemical 
reaction occurs when the heated substrate contact with the combined gas. The 
substrate temperature is an important parameter for this method to gain pure, 
uniform, hard, and strong nanoparticles [47, 53].
• Spray pyrolysis: It is a method often used in industry for large scale produc-
tion of NPs. Generally, nanometals and metal oxides are produced by this 
simple, reproducible, size controllable and low-cost method [54]. This process 
consists of a precursor with flame where the precursor solution is sprayed or 
injected using a nanoporous nebulizer onto the hot substrate into the furnace 
at high pressure to form a droplet. The precursor can be either liquid or vapor. 
After evaporation, the precursor decomposes to recover nanoparticles or films 
on the substrate. Some of the furnaces have laser or plasma to produce high 
temperature to facilitate evaporation [55].
• Biosynthesis: It is an alternative to conventional physical and chemical 
nanoparticle synthesizing methods. Plants are preferred in this green and 
environmentally friendly cost-effective technique to prepare non-toxic and 
biodegradable nanoparticles [56]. In this method, several microorganisms as 
bacteria, fungus, and yeasts, etc. are used along with the precursors to produce 
nanoparticle for bioreduction and capping purposes. The biosynthesized 
nanoparticles have unique and enhanced properties that find a wide range of 
applications in drug delivery systems [57].
5.2.2 Top-down method
This method is also known as a destructive method due to the reduction of 
bulk material to nanometric scale particles. Contrary to bottom-up, large-scale 
production is possible and chemical purification is unnecessary in the top-down 
method. Broad size distribution (10–1000 nm), varied particle shapes, control over 
deposition parameters and reaction costs are disadvantages of this method. There 
are many techniques in this method, but mechanical milling, nanolithography, laser 
ablation and sputtering are among the most frequently used ones.
• Mechanical milling: This process has been used for a long time in mineral, 
ceramic processing, and powder metallurgy industries. The aim of mechanical 
milling of materials consists of minimizing particle size, blending, changing 
particle shapes, and synthesizing nanoparticles in a high energy mill with a con-
venient medium. At nanoparticle synthesis elements are granulated in an inert 
atmosphere. Mechanical milling is an economical method for nanosize produc-
tion of large quantities [58]. The dynamics of mechanical milling vary according 
to energy transfer to the material from the balls [59]. Type of mill, the powder 
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supplied to drive the milling chamber, milling speed, size and size distribution of 
the balls, dry or wet milling, the temperature of milling and the duration of mill-
ing are the factors that affect the energy transfer. Also, deformations, fractures, 
and the type of welding cause variations in particle shape and size [58].
• Nanolithography: This is the fabrication of molecules in a nanometric size 
range of 1 to 100 nm. Lithography is a combination of deposition and etching 
to have high-resolution topography. There are two main methods called as 
masked and maskless lithography. These 2 methods contain many techniques 
inside. While a mask or a mold is needed in masked lithography to fabricate 
patterns, maskless lithography produces unstable patterns without the use of 
mask. Photolithography, soft lithography, and nanoimprint lithography are 
the main techniques in masked lithography. Maskless lithography consists 
of electron beam lithography, ion beam lithography, and scanning probe 
lithography [60].
The process is about printing material in a required shape or structure on a 
light- sensitive material. The main advantage of nanolithography is to make 
several copies with the desired shape and size from a single nanoparticle. 
On the other hand, the necessity of some equipment and their costs are the 
disadvantages of nanolithography [61].
• Laser ablation (LA): The laser irradiates the surface of the sample with a 
changeable wavelength of the laser and the refractive index of the solid or 
liquid target material in this complex PVD process. The laser removes electrons 
from the target material in a high electric field and those scattered electrons 
meet with the atoms of the bulk sample, where the energy transfer occurs. This 
leads to the heating of the surface and vaporization. The material is converted 
to a plasma state at high laser flux. There are some different applications in 
this method such as welding, cladding, cutting, cleaning, and generation of 
nanoparticles. During applications environmental conditions such as vacuum, 
air, gas and liquid can be changed. Pulsed-laser ablation types of solid target 
materials have great potential in the fields of laser-material microprocessing, 
nanotechnology and device fabrication. Besides, Laser Ablation Synthesis in 
Solution (LASiS) is a common and reliable top-down method that provides 
an alternative solution to the conventional chemical synthesis of metal-based 
nanoparticles. Also, organic solvents and water can be used in LASiS for NP 
synthesis and the method can be called as a ‘green’ process [62, 63].
• Sputtering: The principle of this physical process is to use the energy of plasma 
on the surface of a material, to arrange the atoms of the material and deposit 
them on the substrate with energetic ions. After the bombardment with ions, 
the ejection of atoms from the target occurs and then they deposit onto a 
substrate in the vacuum sputtering chamber. This high vacuum-based coat-
ing technique is included in the group of PVD processes. The shape, size, and 
composition of the nanoparticles vary with the layer thickness, temperature, 
and annealing time and substrate type [64].
6. Conclusion
The application of polymeric NPs in cancer therapy has been studied for 
decades. Poly(lactic-co-glycolic acid) (PLGA), chitosan, and polyethylene glycol 
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(PEG) are the most common, FDA-approved polymeric carriers for drug and bio-
agent delivery. PLGA and chitosan contain hydrophobic domains which also capable 
of activating immune cells by their adjuvant character. In general, PLGA-based NPs 
for cancer immunotherapy is based on targeting dendritic cells. Micelles and lipo-
somes are also convenient for the delivery of therapeutics and antigens. Recently, 
immunomodulatory nanoliposomes with 1oo nm size were designed to deliver 
cancer antigens. The researches continued until today has indicated the importance 
of NPs in cancer immunotherapy. The antigen-NP conjugated systems help to intro-
duce the immune-therapeutic agent to antigen-presenting cells efficiently. A high 
immune effect occurs with the presence of immunotherapeutic agent-loaded nano 
delivery systems in comparison to free immunotherapeutic agents. Prolongation, 
antigenicity, adjuvant selection, and inflammation are the most critical parameters 
for designing and engineering NPs.
On the other hand, there are still some issues to be solved in cancer immunother-
apy. In some cases, insufficient information about cancer cells causes drugs not to 
present the expected effect. Scientists are unable to have precise information about 
the behavior of nanoparticles in the living system. In addition to these, there are 
difficulties in adjusting the toxicity, characterization, and monitoring behavior of 
nanomaterials in biochemical pathways. Moreover, failure to comply with the rules 
in drug use in such practices makes the work of the researchers even more difficult.
Besides, nanotechnology is promising for oncological applications for precise 
diagnoses and struggles with cancer cells. In light of the information mentioned in 
the literature, it is seen that interdisciplinary approaches and researches about the 
design and development of nanoparticle-based cancer immunotherapy are promis-
ing. Nanotechnology-based studies enable a therapeutic efficacy with a low dose of 
therapeutics, avoid cytotoxicity, and not to destroy the healthy cells of the patient. 
The quality and duration of cancer patients’ lives can be improved by developing 
new methodologies in cancer immunotherapy based on nanoparticles.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
15
Immune System Modulations in Cancer Treatment: Nanoparticles in Immunotherapy
DOI: http://dx.doi.org/10.5772/intechopen.94560
References
[1] P. Huang et al., “Nano-, micro-, 
and macroscale drug delivery systems 
for cancer immunotherapy,” Acta 
Biomaterialia. 2019, doi: 10.1016/j.
actbio.2018.12.028.
[2] J. Nam, S. Son, K. S. Park, W. Zou, 
L. D. Shea, and J. J. Moon, “Cancer 
nanomedicine for combination 
cancer immunotherapy,” Nature 
Reviews Materials. 2019, doi: 10.1038/
s41578-019-0108-1.
[3] H. Zhang and J. Chen, “Current 
status and future directions of cancer 
immunotherapy,” Journal of Cancer. 
2018, doi: 10.7150/jca.24577.
[4] R. Kokate, “A Systematic Overview of 
Cancer Immunotherapy: An Emerging 
Therapy,” Pharm. Pharmacol. Int. J., 
2017, doi: 10.15406/ppij.2017.05.00112.
[5] F. Bray, J. Ferlay, I. Soerjomataram, 
R. L. Siegel, L. A. Torre, and A. 
Jemal, “Global cancer statistics 2018: 
GLOBOCAN estimates of incidence and 
mortality worldwide for 36 cancers in 
185 countries,” CA. Cancer J. Clin., 2018, 
doi: 10.3322/caac.21492.
[6] V. K. Chaturvedi, A. Singh, V. 
K. Singh, and M. P. Singh, “Cancer 
Nanotechnology: A New Revolution for 
Cancer Diagnosis and Therapy,” Curr. 
Drug Metab., 2018, doi: 10.2174/1389200
219666180918111528.
[7] A. Sudhakar, “History of Cancer, 
Ancient and Modern Treatment 
Methods,” J. Cancer Sci. Ther., 2009, doi: 
10.4172/1948-5956.100000e2.
[8] O. Baykara, “Kanser Tedavisinde 
Güncel Yaklaşımlar,” Balıkesır Sağlık 
Bilim. Derg., 2017, doi: 10.5505/bsbd. 
2016.93823.
[9] J. R. Robbins, J. M. Longo, and M. 
Straza, “Radiation therapy,” in Cancer 
Regional Therapy: HAI, HIPEC, HILP, 
ILI, PIPAC and Beyond, 2019.
[10] K. E. Burton, “Radiotherapy,” in 
Management of Adult Glioma in Nursing 
Practice, 2019.
[11] V. T. DeVita and E. Chu, “A history 
of cancer chemotherapy,” Cancer 
Research. 2008, doi: 10.1158/0008-5472.
CAN-07-6611.
[12] B. A. Chabner and T. G. Roberts, 
“Chemotherapy and the war on cancer,” 
Nature Reviews Cancer. 2005, doi: 
10.1038/nrc1529.
[13] A. Nicolini, G. Rossi, P. Ferrari, 
R. Morganti, and A. Carpi, “A new 
immunotherapy schedule in addition 
to first-line hormone therapy for 
metastatic breast cancer patients in a 
state of clinical benefit during hormone 
therapy,” J. Mol. Med., 2020, doi: 
10.1007/s00109-020-01881-3.
[14] N. Zaidi and E. M. Jaffee, 
“Immunotherapy transforms cancer 
treatment,” Journal of Clinical 
Investigation. 2019, doi: 10.1172/
JCI126046.
[15] E. F. McCarthy, “The toxins of 
William B. Coley and the treatment of 
bone and soft-tissue sarcomas.,” Iowa 
Orthop. J., 2006.
[16] S. J. Oiseth and M. S. Aziz, “Cancer 
immunotherapy: a brief review of the 
history, possibilities, and challenges 
ahead,” J. Cancer Metastasis Treat., 2017, 
doi: 10.20517/2394-4722.2017.41.
[17] T. A. Waldmann, “Immunotherapy: 
Past, present and future,” Nature 
Medicine. 2003, doi: 10.1038/nm0303-269.
[18] M. Barbaros, Burak; Dikmen, 
“Kanser İmmünoterapisi,” Erciyes 
Üniversitesi Fen Bilim. Enst. Derg., 2015.
[19] C. R. Parish, “Cancer immuno-
therapy: The past, the present and the 
future,” Immunology and Cell Biology.  
Cell Interaction - Molecular and Immunological Basis for Disease Management
16
2003, doi: 10.1046/j.0818-9641.2003. 
01151.x.
[20] N. E. Papaioannou, O. V. Beniata, 
P. Vitsos, O. Tsitsilonis, and P. Samara, 
“Harnessing the immune system to 
improve cancer therapy,” Annals of 
Translational Medicine. 2016, doi: 
10.21037/atm.2016.04.01.
[21] M. Sambi, L. Bagheri, and M. R. 
Szewczuk, “Current challenges in cancer 
immunotherapy: Multimodal approaches 
to improve efficacy and patient response 
rates,” Journal of Oncology. 2019, doi: 
10.1155/2019/4508794.
[22] M. J. Smyth and M. W. L. Teng, 
“2018 Nobel Prize in physiology or 
medicine,” Clinical and Translational 
Immunology. 2018, doi: 10.1002/cti2.1041.
[23] S. Tan, D. Li, and X. Zhu, “Cancer 
immunotherapy: Pros, cons and beyond,” 
Biomedicine and Pharmacotherapy. 2020, 
doi: 10.1016/j.biopha.2020.109821.
[24] D. V. Yuzhakova, M. V. Shirmanova, 
T. F. Sergeeva, E. V. Zagaynova, and 
K. A. Lukyanov, “Immunotherapy 
of cancer (Review),” Sovremennye 
Tehnologii v Medicine. 2016, doi: 10.17691/
stm2016.8.1.23.
[25] C. Lee Ventola, “Cancer immuno-
therapy, part 1: Current strategies and 
agents,” P T, 2017.
[26] A. A. Özlük, M. G. Oytun, and D. 
Günenç, “Kanser immünoterapisi,” 
İstanbul Bilim Üniversitesi 
Florence Nightingale Transplant. 
Derg., 2017, doi: 10.5606/FNG.
TRANSPLANTASYON.2017.004.
[27] I. Kimiz-Gebologlu, S. Gulce-Iz, and 
C. Biray-Avci, “Monoclonal antibodies 
in cancer immunotherapy,” Molecular 
Biology Reports. 2018, doi: 10.1007/
s11033-018-4427-x.
[28] Ö. Met, K. M. Jensen, C. A. 
Chamberlain, M. Donia, and I. M. 
Svane, “Principles of adoptive T 
cell therapy in cancer,” Seminars in 
Immunopathology. 2019, doi: 10.1007/
s00281-018-0703-z.
[29] P. Ataca and O. Arslan, “Chimeric 
Antigen Receptor T Cell (Car T Cell)  
Therapy In Hematology,” Turkish J.  
Hematol., 2015, doi: 10.4274/tjh. 
2015.0049.
[30] E. Wrona and P. Potemski, “A 
novel immunotherapy — The history 
of CAR T-cell therapy,” Oncology in 
Clinical Practice. 2019, doi: 10.5603/
OCP.2019.0016.
[31] K. Kaur and G. L. Khatik, “Cancer 
Immunotherapy: An Effective Tool in 
Cancer Control and Treatment,” Curr. 
Cancer Ther. Rev., vol. 16, no. 1, pp. 62-69, 
2020.
[32] G. Marelli, A. Howells, N. R. 
Lemoine, and Y. Wang, “Oncolytic 
viral therapy and the immune system: 
A double-edged sword against cancer,” 
Frontiers in Immunology. 2018, doi: 
10.3389/fimmu.2018.00866.
[33] S. Khan and D. E. Gerber, 
“Autoimmunity, checkpoint inhibitor 
therapy and immune-related adverse 
events: A review,” Seminars in 
Cancer Biology. 2019, doi: 10.1016/j.
semcancer.2019.06.012.
[34] K. KAHVECİ and M. Türkoğlu, 
“İmmün Kontrol Noktası İnhibitörleri 
Ctla-4 ve Pd-1/Pd-l1’in İmmünoterapideki 
Yeri,” Mehmet Akif Ersoy Üniversitesi Fen 
Bilim. Enstitüsü Derg., vol. 10, no. 2,  
pp. 210-218.
[35] J. A. Seidel, A. Otsuka, and  
K. Kabashima, “Anti-PD-1 and anti-
CTLA-4 therapies in cancer: Mechanisms 
of action, efficacy, and limitations,” 
Frontiers in Oncology. 2018, doi: 10.3389/
fonc.2018.00086.
[36] T. A. Waldmann, “Cytokines in 
cancer immunotherapy,” Cold Spring 
17
Immune System Modulations in Cancer Treatment: Nanoparticles in Immunotherapy
DOI: http://dx.doi.org/10.5772/intechopen.94560
Harb. Perspect. Biol., 2018, doi: 10.1101/
cshperspect.a028472.
[37] S. Lee and K. Margolin, “Cytokines 
in cancer immunotherapy,” Cancers. 
2011, doi: 10.3390/cancers3043856.
[38] J. Ciccolini, D. Barbolosi, N. 
André, S. Benzekry, and F. Barlesi, 
“Combinatorial immunotherapy 
strategies: most gods throw dice, but 
fate plays chess,” Annals of Oncology. 
2019, doi: 10.1093/annonc/mdz297.
[39] C. Wang, Y. Ye, Q. Hu, A. Bellotti, and 
Z. Gu, “Tailoring Biomaterials for Cancer 
Immunotherapy: Emerging Trends and 
Future Outlook,” Advanced Materials. 
2017, doi: 10.1002/adma.201606036.
[40] S. K. Rajendrakumar et al., “Self-
assembled, adjuvant/antigen-based 
nanovaccine mediates anti-tumor 
immune response against melanoma 
tumor,” Polymers (Basel)., vol. 10, no. 10, 
p. 1063, 2018.
[41] Y. Yu and J. Cui, “Present and future 
of cancer immunotherapy: A tumor 
microenvironmental perspective,” 
Oncology Letters. 2018, doi: 10.3892/
ol.2018.9219.
[42] R. Agarwal, V. Singh, P. Jurney, 
L. Shi, S. V. Sreenivasan, and K. Roy, 
“Mammalian cells preferentially 
internalize hydrogel nanodiscs over 
nanorods and use shape-specific uptake 
mechanisms,” Proc. Natl. Acad. Sci. U. S. 
A., 2013, doi: 10.1073/pnas.1305000110.
[43] W. Park, Y.-J. Heo, and D. K. Han, 
“New opportunities for nanoparticles in 
cancer immunotherapy,” Biomater. Res., 
2018, doi: 10.1186/s40824-018-0133-y.
[44] S. P. Surendran, M. J. Moon, R. Park, 
and Y. Y. Jeong, “Bioactive nanoparticles 
for cancer immunotherapy,” International 
Journal of Molecular Sciences. 2018, doi: 
10.3390/ijms19123877.
[45] V. Manolova, A. Flace, M. Bauer, 
K. Schwarz, P. Saudan, and M. F. 
Bachmann, “Nanoparticles target distinct 
dendritic cell populations according to 
their size,” Eur. J. Immunol., 2008, doi: 
10.1002/eji.200737984.
[46] B. D. Chithrani, A. A. Ghazani, 
and W. C. W. Chan, “Determining the 
size and shape dependence of gold 
nanoparticle uptake into mammalian 
cells,” Nano Lett., 2006, doi: 10.1021/
nl052396o.
[47] A. M. Ealias and M. P. 
Saravanakumar, “A review on the 
classification, characterisation, 
synthesis of nanoparticles and their 
application,” in IOP Conference Series: 
Materials Science and Engineering, 2017, 
doi: 10.1088/1757-899X/263/3/032019.
[48] H. R. Ghaffarian, M. Saiedi, M. 
A. Sayyadnejad, and M. A. Rashidi, 
“Synthesis of ZnO nanoparticles by 
spray pyrolysis method,” Iran. J. Chem. 
Chem. Eng., 2011.
[49] L. Baraket and A. Ghorbel, “Control 
preparation of aluminium chromium 
mixed oxides by sol-gel process,” Stud. 
Surf. Sci. Catal., 1998, doi: 10.1016/
s0167-2991(98)80233-4.
[50] S. Prasad, V. Kumar, S. 
Kirubanandam, and A. Barhoum, 
“Engineered nanomaterials: 
nanofabrication and surface 
functionalization,” in Emerging 
Applications of Nanoparticles and 
Architecture Nanostructures, Elsevier, 
2018, pp. 305-340.
[51] H. Bagheri Farahani, M. Shahrokhi, 
and A. Molaei Dehkordi, “Experimental 
investigation and process intensification 
of barium sulfate nanoparticles 
synthesis via a new double coaxial 
spinning disks reactor,” Chem. Eng. 
Process. - Process Intensif., 2017, doi: 
10.1016/j.cep.2017.02.007.
[52] M. Benelmekki and A. Erbe, 
“Nanostructured thin films–
background, preparation and relation 
Cell Interaction - Molecular and Immunological Basis for Disease Management
18
to the technological revolution of the 
21st century,” in Frontiers of Nanoscience, 
2019.
[53] A. Kumar and D. Nanda, 
“Methods and fabrication techniques 
of superhydrophobic surfaces,” in 
Superhydrophobic Polymer Coatings, 2019.
[54] K. Okuyama and W. W. Lenggoro, 
“Preparation of nanoparticles via spray 
route,” Chem. Eng. Sci., 2003, doi: 
10.1016/S0009-2509(02)00578-X.
[55] D. S. Kumar, B. J. Kumar, and H. 
M. Mahesh, “Quantum nanostructures 
(QDs): an overview,” in Synthesis of 
Inorganic Nanomaterials, Elsevier, 2018, 
pp. 59-88.
[56] T. M. Abdelghany et al., “Recent 
advances in green synthesis of silver 
nanoparticles and their applications: 
about future directions. A review,” 
Bionanoscience, vol. 8, no. 1, pp. 5-16, 
2018.
[57] N. I. Hulkoti and T. C. Taranath, 
“Biosynthesis of nanoparticles using 
microbes—a review,” Colloids Surfaces B 
Biointerfaces, vol. 121, pp. 474-483, 2014.
[58] T. P. Yadav, R. M. Yadav, and D. 
P. Singh, “Mechanical milling: a top 
down approach for the synthesis of 
nanomaterials and nanocomposites,” 
Nanosci. Nanotechnol., vol. 2, no. 3, pp. 
22-48, 2012.
[59] S. C. Tjong and H. Chen, 
“Nanocrystalline materials and 
coatings,” Mater. Sci. Eng. R Reports, vol. 
45, no. 1-2, pp. 1-88, 2004.
[60] R. J. Varghese, S. Parani, S. 
Thomas, O. S. Oluwafemi, and J. Wu, 
“Introduction to nanomaterials: synthesis 
and applications,” in Nanomaterials for 
Solar Cell Applications, Elsevier, 2019,  
pp. 75-95.
[61] G. Venugopal, M.-H. Jung, M. 
Suemitsu, and S.-J. Kim, “Fabrication of 
nanoscale three-dimensional graphite 
stacked-junctions by focused-ion-beam 
and observation of anomalous transport 
characteristics,” Carbon N. Y., vol. 49, 
no. 8, pp. 2766-2772, 2011.
[62] A. H. Hamad, K. S. Khashan, and 
A. A. Hadi, “Laser ablation in different 
environments and generation of 
nanoparticles,” Appl. Laser Ablation 
Thin Film Depos. Nanomater. Synth. Surf. 
Modif., p. 177, 2016.
[63] G. Mansoureh and V. Parisa, 
“Synthesis of metal nanoparticles using 
laser ablation technique,” in Emerging 
Applications of Nanoparticles and 
Architecture Nanostructures, Elsevier, 
2018, pp. 575-596.
[64] M. T. Nguyen and T. Yonezawa, 
“Sputtering onto a liquid: interesting 
physical preparation method for multi-
metallic nanoparticles,” Sci. Technol. Adv. 
Mater., vol. 19, no. 1, pp. 883-898, 2018.
